Management of Thrombocytopenia

Assessment and Management

The International Society on Thrombosis and Haemostasis recommends assessing for bleeding risk factors such as concurrent coagulopathy, liver or renal impairment, infection, and need for invasive procedures in patients with thrombocytopenia 1, 2
Cancer patients, especially those on anticoagulation, are at higher risk of bleeding complications due to thrombocytopenia 1, 2, 3
Patients with a history of bleeding are also at increased risk of bleeding complications due to thrombocytopenia 2

The American Society of Hematology recommends full therapeutic anticoagulation for cancer-associated thrombosis with platelet count 60 × 10³/μL, with no dose adjustment or platelet transfusion support needed at this level 1, 4, 5
Low molecular weight heparin (LMWH) is the preferred anticoagulant for cancer-associated thrombosis with thrombocytopenia 4, 5
For non-cancer thrombosis with platelet count 60 × 10³/μL, full therapeutic anticoagulation can be safely administered, with regular monitoring of platelet counts 1, 5

If platelet count drops below 50 × 10³/μL while on anticoagulation, consider full-dose anticoagulation with platelet transfusion support to maintain count ≥40-50 × 10³/μL for high-risk thrombosis 5
For lower-risk thrombosis, consider reducing LMWH to 50% of therapeutic dose or prophylactic dosing if platelet count drops below 50 × 10³/μL 5

Immediate referral to emergency department is recommended if patient is acutely unwell, active significant bleeding is present, or rapid decline in platelet count is observed 3
Referral to hematology is recommended if cause of thrombocytopenia is unclear, platelet count continues to decline despite management, or platelet count drops below 50 × 10³/μL 3